Peripheral neuropathy
Conditions
Interventions
Patients in group 1 receive vitamin D-supplements for six months. In addition,
every patient will complete the ICPNQ Questionnaire and VAS score after 2 and 6
months to determine neuropathy grading.
Multiple myeloma
Peripheral neuropathy
Vitamin D
Sponsors
Medisch Centrum Leeuwarden
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Patients with multiple myeloma with grade 2/3 peripheral neuropathy and a 25-hydroxyvitamin D level
Exclusion criteria
Exclusion criteria: Contraindications for the use of vitamin D and/or patients who are already using any formulation of vitamin D
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The efficacy of vitamin D supplementation on the severity of PN in vitamin D-deficient MM patients with grade 2 or 3 PN. The main endpoint is the percent change in the number of patients whose PN decreases with at least 1 grade. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objectives are to assess an optimal dosing regimen of vitamin D supplementation in MM patients and to search for differences in the effect of vitamin D on PN for each drug. | — |
Countries
The Netherlands
Outcome results
None listed